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ABSTRACT: Transcriptional regulation is central to the
complex behavior of natural biological systems and synthetic
gene circuits. Platforms for the scalable, tunable, and simple
modulation of transcription would enable new abilities to
study natural systems and implement artiﬁcial capabilities in
living cells. Previous approaches to synthetic transcriptional
regulation have relied on engineering DNA-binding proteins,
which necessitate multistep processes for construction and
optimization of function. Here, we show that the CRISPR/Cas
system of Streptococcus pyogenes can be programmed to direct both activation and repression to natural and artiﬁcial eukaryotic
promoters through the simple engineering of guide RNAs with base-pairing complementarity to target DNA sites. We
demonstrate that the activity of CRISPR-based transcription factors (crisprTFs) can be tuned by directing multiple crisprTFs to
diﬀerent positions in natural promoters and by arraying multiple crisprTF-binding sites in the context of synthetic promoters in
yeast and human cells. Furthermore, externally controllable regulatory modules can be engineered by layering gRNAs with small
molecule-responsive proteins. Additionally, single nucleotide substitutions within promoters are suﬃcient to render them
orthogonal with respect to the same gRNA-guided crisprTF. We envision that CRISPR-based eukaryotic gene regulation will
enable the facile construction of scalable synthetic gene circuits and open up new approaches for mapping natural gene networks
and their eﬀects on complex cellular phenotypes.
KEYWORDS: synthetic transcription factors, CRISPR/Cas9, RNA-guided multiplex gene regulation, synthetic gene regulation,
endogenous gene regulation, synthetic biology
Complex and sophisticated phenotypes in eukaryotic cellsmanifest from layered regulatory networks and speciﬁc
expression programs involving the regulated transcription of
many genes.1 As major players in these networks, eukaryotic
transcriptional factors (TFs) can integrate multiple signals and
perform complex, combinatorial functions on promoters, where
regulatory information is encoded in the form of binding sites
for TFs and interactions between TFs, to modulate gene
expression patterns.1−3
Rewiring endogenous transcriptional networks by natural or
synthetic TFs is a powerful strategy for interrogating cellular
functions and controlling cellular phenotypes.4−14 Previously,
natural DNA-binding domains (DBDs, mainly from bacterial
sources, such as TetR, LacI, and LexA) have been used to
recruit eﬀector (e.g., activator and repressor) domains to the
regulatory regions of eukaryotic genes in order to modulate
their transcription.15−17 This necessitates the placement of
DBD-speciﬁc operator site(s) in the cis-regulatory region of the
promoters for speciﬁc genes which is a labor- and time-
intensive process, especially if the regulation of multiple genes
is desired. Moreover, engineering and modulating complex
transcriptional networks requires tunable, extensible, and
orthogonal transcription factors. However, only a few
orthogonal variants of natural DBDs are well-characterized
and changing their speciﬁcity has proven to be challenging.18 As
such, the use of natural DBD-based TFs for wiring complex
transcriptional networks and synthetic gene circuits has been
limited.
To address these limitations, synthetic TFs based on Zinc
Fingers (ZFs) and Transcriptional Activator-Like Eﬀectors
(TALEs) have been developed.19−25 The ability to program the
speciﬁcity of ZFs and TALEs to potentially target any sequence
makes these DBDs appealing for designing libraries of
orthogonal transcription factors. Synthetic ZF- and TALE-
based TFs have been shown to work in a wide range of
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eukaryotes;22,26,27 however, obtaining a TF for a given target
site requires tedious selection processes or multistage DNA
assembly protocols.28,29 Furthermore, the scale of regulation
that can be achieved by these TFs is potentially limited by the
metabolic burden imposed on the cells and the number of TFs
that can be simultaneously encoded in a given cell.30
Here, we present a strategy for modulating eukaryotic
transcription at natural and synthetic promoters using
programmable and tunable synthetic transcription factors
based on a bacterial CRISPR (Clustered Regularly Interspaced
Short Palindromic Repeats)/Cas system. Many bacteria use
CRISPR-based immune systems to degrade genetic materials of
invading phages.31,32 In these systems, short RNAs expressed
from CRISPR loci are used to target an endonuclease protein
(Cas9) against invading genetic material. Recently, it has been
shown that Cas9 can be used as a programmable tool for
genome editing across various organisms.33−38 In this context,
small customizable guide RNAs (gRNAs) can be used to
program and target Cas9 endonuclease to speciﬁc loci in living
cells to induce double (or single)-stranded breaks in DNA.
Upon cleavage, error-prone or template-directed repair path-
ways are triggered, generating variants of the original target loci.
Recently, Qi et al.39 showed that an endonuclease-deﬁcient
Cas9 (dCas9, with D10A H841A mutations relative to the wild-
type Cas9) can be used as a programmable “CRISPRi” tool for
gene silencing in Escherichia coli. When targeted to a promoter
or ORF of a gene of interest, dCas9 can block progression of
RNA polymerase and hence silence expression of the targeted
gene. They also provide evidence that CRISPRi is functional in
human cells, albeit with much lower eﬃciency compared with
E. coli. In addition, Bikard et al. demonstrated that along with
programmed transcriptional repression, transcriptional activa-
tion can be achieved in E. coli by fusing the omega subunit of
RNA polymerase to the endonuclease-deﬁcient Cas9.40
Here, we achieved versatile, programmable, and multi-
plexable tools for gene regulation in eukaryotes by functionaliz-
Figure 1. Schematic view of the programmable CRISPR/Cas-based eukaryotic transcriptional regulation system implemented in S. cerevisiae. (A)
CrisprTF (dCas9_VP64) expression is induced by growing cells in galactose (Gal) + anhydrotetracycline (aTc) media. CrisprTFs are guided to the
target sites by guide RNAs (gRNAs), which are constitutively expressed from the pRPR1 promoter and bind to the respective target sites. Speciﬁcity
of crisprTFs is primarily determined by the 20 bp Speciﬁcity Determinant Sequence (SDS) at the 5′-end of the gRNA along with the presence of a
Proto-spacer Adjacent Motif (PAM) (NGG) at the target site. (B) Map of pCYC1m illustrating the relative positions of known regulatory elements.
TATA: TATA box. TSS: Transcription Start Site. KS: Kozak Sequence. Blue lines indicate target sites for each gRNA (c1-c8). (C) Left panel:
Regulation of gfp expression from pCYC1m by crisprTFs based on the individual gRNAs shown in (B). Yeast cells expressing crisprTFs and
containing the reporter construct were transformed with plasmids expressing gRNAs labeled as shown in the x-axis. Targeting crisprTFs to
sequences upstream of the TATA boxes (by c3, c4, and c8 gRNAs) resulted in higher gfp expression than the no gRNA control. On the other hand,
targeting crisprTFs to sequences spanning the TATA box and the Kozak sequence (by c1, c6, and c7 gRNAs) resulted in reduced gfp expression
relative to the no gRNA control. Error bars indicate the standard error of the mean for three independent biological replicates. Asterisks (*) on each
bar indicate statistically signiﬁcant changes in gfp expression relative to the no gRNA control (based on the two-sided Welch’s t test, p-value < 0.05).
Right panel: Coexpression of multiple gRNAs resulted in synergistic gene regulation. Pairwise combinations of non-neutral gRNAs were expressed
from pRPR1 promoters on pRS423 and pRS425 backbones. Green and red asterisks (*) indicate statistically signiﬁcant changes in gfp expression in
samples with coexpressed gRNAs relative to the ﬁrst gRNA only and the second gRNA only, respectively (two-sided Welch’s t test, p-value < 0.05).
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ing dCas9 with eﬀector domains and targeting both natural and
synthetic promoters. As a proof of concept, we made an RNA-
guidable transcription factor by fusing dCas9 to an activator
domain. Using this CRISPR-based transcription factor
(crisprTF), we teased apart the regulatory maps of several
natural eukaryotic promoters (in Saccharomyces cerevisiae and
HEK293T cells) without the need to modify promoter
architectures. Unlike previous generations of customizable
DBDs (i.e., ZFs and TALEs) that require multistage design and
cloning strategies, crisprTFs can be readily customized and
retargeted to diﬀerent loci and regulatory regions in vivo using
speciﬁc gRNAs with homology to target sites (Figure 1). dCas9
thus oﬀers a powerful tool for targeting functions of interest to
speciﬁc genomic loci in living cells, which can potentially be
used to regulate gene expression at will, construct scalable
synthetic gene circuits, or rewire endogenous regulatory
networks.
To implement crisprTFs in Saccharomyces cerevisiae, we fused
the SV40 nuclear localization sequence (NLS) and four tandem
copies of Herpes Simplex Viral Protein 16 (VP64, a commonly
used eukaryotic transcription activator domain) to a codon-
optimized S. pyogenes dCas9 (Figure 1A).41 The crisprTF
cassette was then cloned under the control of pTPGI, a
synthetic promoter which can be induced by growing cells in
galactose + anhydrotetracycline (aTc) media23 and integrated
into the yeast genome. To assess the activity of crisprTF, gfp
was placed under the control of a minimal CYC1 promoter
(pCYC1m) and the whole cassette was integrated into the yeast
genome. pCYC1m retains one of the two endogenous TATA
boxes of the wild-type CYC1 promoter and lacks binding sites
for endogenous regulatory factors in the upstream activating
sequence (UAS).42,43 gRNAs were expressed constitutively
from the RNA polymerase III-dependent pRPR1 promoter and
the 3′-ends of the gRNAs were deﬁned by the pRPR1
terminator.44
The expression of gRNAs targeting diﬀerent regions in the
pCYC1m (as shown in Figure 1B) resulted in various
statistically signiﬁcant levels of reporter ﬂuorescence compared
to the no gRNA control (Figure 1C, left panel). Targeting
crisprTFs to the sequences upstream of the TATA boxes (by
c3, c4, and c8 gRNAs) led to the activation of the reporter.
However, targeting crisprTFs to the sequences spanning the
TATA box and the Kozak sequence (KS) resulted in the
repression of gfp expression to various degrees. Stronger
repression was achieved when crisprTFs were targeted to the
proximity of TATA box (using c7 gRNA) and to the vicinity of
Figure 2. Regulation of yfp expression from a minimal MLP promoter (pMLPm) by crisprTFs in HEK293T cells. (A) dCas9_VP64 is expressed in
HEK293T cells by the pCMV promoter and directed to target sequences in pMLPm. The mKATE (red) and mBFP2 (blue) ﬂuorophores act as
ﬂow-cytometry gating controls for successful plasmid transfections. (B) Map of pMLPm illustrating the relative positions of known regulatory
elements. Blue lines indicate target sites for each gRNA. (C) Regulation of yfp expression from pMLPm by crisprTFs based on the gRNAs shown in
(B). HEK293T cells were cotransfected with the plasmids shown in (A), with speciﬁc gRNAs labeled as shown in the x-axis. Targeting crisprTFs to
sequences upstream of the TATA box (by m1, m2, m6, and m7 gRNAs) resulted in higher yfp expression compared with the no gRNA control.
Error bars indicate the standard error of the mean for three independent biological replicates. Asterisks (*) on each bar indicate statistically
signiﬁcant changes in yfp expression relative to the no gRNA control (based on the two-sided Welch’s t test, p-value <0.05).
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the TATA box and the transcription start site (using c2 and c6
gRNAs), likely due to interference of crisprTFs with the
formation of the transcriptional initiation complex.45 No
activation was observed with any of the eight tested gRNAs
when dCas9, without a fused activator domain, was targeted to
pCYC1m (Figure S1, Supporting Information). All the tested
gRNAs in this strain repressed gfp expression to some extent
(Figure S1, Supporting Information), with highest repression
observed with c6 and c7. These results demonstrate that dCas9
is able to repress transcription but requires an activation
domain (VP64) to activate transcription of a target locus and
further supports the hypothesis that dCas9 (or as a fusion to
VP64) can act as a repressor by interfering with the formation
of the transcriptional initiation complex. Similar results were
achieved with the GAL1 promoter (pGAL1) and its variants,
where targeting crisprTFs to sequences upstream and down-
stream of TATA box led to activation and repression of the
GFP reporter, respectively (Figure S2, Supporting Informa-
tion). These results indicate that a single crisprTF can be
programmed to act as both an activator and a repressor by
targeting it to diﬀerent positions across endogenous promoters.
The activity of a promoter is determined by combinatorial
interactions between transcriptional regulatory factors bound to
that promoter. We thus investigated the eﬀects of binding of
multiple crisprTFs targeted to the same promoter. To this end,
pairwise combinations of gRNAs with non-neutral eﬀects
(those that showed either activation or repression in the left
panel of Figure 1C) were coexpressed. As shown in the right
panel of Figure 1C, coexpression of repressor gRNAs resulted
in synergistic repression of the reporter (up to 7× repression
was achieved with coexpression of the c5 and c6 pair as well as
the c6 and c7 pair). On the other hand, when a repressor gRNA
was coexpressed with an activator gRNA (e.g., the c3 and c6
pair), an intermediate level of GFP expression was achieved,
indicating an antagonistic interaction between the two gRNAs.
Moreover, the eﬀects of repressor gRNAs were dominant over
activator gRNAs, suggesting that interruption of the formation
of the transcription initiation complex has a stronger eﬀect than
activation.46 Coexpression of two activator gRNAs (e.g., c3 and
c4) did not result in synergistic activation of the reporter, which
suggests that the relative positions and interactions of bound
activators are important for determining synergistic activation.46
Consistent with our results, it has been shown that synergistic
activation from synthetic promoters with multiple GAL4
operator sites depends on the distance and helical phase of
the operator sites.47 Furthermore, in another study it has been
shown that not all of the combinations of TALE-activators
targeted to the same promoter result in synergistic activation.25
We next sought to investigate the activity of crisprTFs in
human cells. To this end, a human-codon-optimized crisprTF
cassette was placed on a plasmid under the control of the
constitutive cytomegalovirus immediate-early promoter
(pCMV). The gRNAs were expressed constitutively from a
separate plasmid by the RNA polymerase III-dependent U6
promoter (pU6), as previously described37,48 (Figure 2A). After
transfection of these plasmids into HEK293T cells, we
investigated the regulatory architecture of the minimal
adenovirus major late promoter (pMLPm)49 by targeting
crisprTFs to diﬀerent positions across this promoter (Figure
3A). YFP was used as the readout for pMLPm promoter
activity.
Consistent with the results obtained in S. cerevisiae, crisprTFs
activated gene expression when targeted to sequences upstream
of the pMLPm TATA box (using m1, m2, m6, or m7 gRNA)
or downstream of the transcription start site (m8 gRNA)
(Figure 2B and C). Since the basal expression level of the
pMLPm promoter is low, it was challenging to detect
signiﬁcant repression from this promoter. Thus, to demonstrate
that crisprTFs can function as transcriptional repressors in
mammalian cells, we placed mKATE under the control of a
constitutive mammalian promoter, phosphoglycerate kinase 1
(pPGK1),50 and targeted crisprTFs to this promoter (Figure
3A). pPGK1 is a strong, constitutive, TATA-less promoter that
contains a CCAAT box51 and ﬁve GC-boxes.52 These sites are
the binding sites for the endogenous human transcription
factors CBP and SP1, respectively. Targeting dCas9 alone,
dCas9 fused to VP64 domain, or dCas9 fused to KRAB domain
to the CCAAT box or the GC-boxes resulted in signiﬁcant
repression of the reporter gene (Figure 3B), presumably by
preventing endogenous transcription factors from binding to
speciﬁc DNA recognition elements51,52 within the pPGK1
promoter.
We further sought to explore the tunability of crisprTFs in
the context of synthetic promoters. In order to do so, we
engineered multiple artiﬁcial binding sites (operators),
pCYC1m separated by 20 base-pair sequences, upstream of
the pCYC1m promoter in S. cerevisiae (Figure 4A). Expression
of a gRNA, which targeted these arrayed operator sites resulted
in synergistic activation of the bfp reporter (Figure 4B). Higher
levels of bfp expression (up to 70-fold activation with 12×
gRNA operator sites) were achieved by increasing the number
of gRNA binding sites upstream of the engineered pCYC1m.
This level of activation in yeast is comparable to the activation
reported for commonly used endogenous yeast promoters (e.g.,
Figure 3. CrisprTF-mediated repression of the constitutive pPGK1
promoter in HEK293T cells. (A) Map of the pPGK1 promoter
illustrating the relative positions of known regulatory elements. (B)
CrisprTF-based targeted repression of the constitutive pPGK1
promoter. Constructs expressing diﬀerent dCas9-based proteins
(dCas9, dCas9_VP64, and dCas9_KRAB) were cotransfected with
plasmids containing pPGK1_mKATE and constructs expressing no
gRNAs or gRNAs targeting the CCAAT box or the GC-box gRNA.
Signiﬁcant repression of the pPGK1 promoter relative to the no gRNA
control was observed with all of the three diﬀerent dCas9 constructs
(dCas9, dCas9-VP64, and dCas9-KRAB). Error bars indicate the
standard error of the mean for three independent biological replicates.
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pGAL153 and pCUP154) and synthetic promoters that are
modulated by engineered bacterial DNA binding domains (e.g.,
TetON/TetOFF promoters16). Our results are consistent with
previous observations that arraying multiple binding sites for a
transcriptional activator upstream of a promoter results in
longer transcriptional bursts from the promoter and thus leads
to higher levels of expression from the targeted promoter.55 We
saw similar synergistic activation in HEK293T cells when
multiple gRNA operator sites were placed upstream of pMLPm
(Figure 4C and D), with up to 56× activation attained with 3×
gRNA operator sites. The level of activation that is achieved by
crisprTFs in human cells is comparable to the levels of
activation reported for ZF- and TALE-activators,19,24,25 where
higher activation levels can be achieved by increasing the
number of operator sites or by targeting multiple synthetic
transcription factors to the same locus.25,27 These results
demonstrate that crisprTFs can be used to build synthetic
promoters with tunable strengths by the straightforward
engineering of gRNA-binding sites.
In many applications, control of the activity of a transcription
factor by an inducer (e.g., a small molecule) is desired. With
crisprTFs, one viable strategy is to constitutively express the
protein component of the system (i.e., dCas9) and then
modulate the amount of gRNA available for binding to dCas9
and thus the activity achieved at the target DNA. To test this
strategy, we constructed an anhydrotetracycline (aTc)-indu-
cible pRPR1 promoter by placing a TetR operator site
(1xTetO) in the pRPR1 promoter, as previously described,56
and constitutively expressing Tet repressor (TetR) (Figure 5A).
Furthermore, to make the expression of dCas9_VP64
independent of aTc, we placed it under the control of
pGAL1. We tested this system in cells containing a pCYC1m
promoter with six a1_gRNA operator sites, named 6x(a1_op)
_pCYC1m, controlling expression of bfp. As shown in Figure
5B, bfp expression increased about 20-fold when S. cerevisiae
cells were induced with galactose and aTc, compared with
galactose only, thus demonstrating external control of crisprTF
activity.
Although the exact parameters that determine the sequence
speciﬁcity of Cas9 are not yet well-characterized, it has been
shown that the speciﬁcity of Cas9 for target loci is mainly
determined by the PAM motif (NGG) and the 12 base-pairs
preceding this motif (seed sequence). Mutations in any of these
15 positions can severely aﬀect the targeting eﬃciency and
binding speciﬁcity of Cas9.35,37,57,58 To test whether this
property can be used to create orthogonal synthetic promoters,
new PAM motifs or single or multiple point mutations (marked
with asterisks, Figure 6A) were introduced into the wild-type
pCYC1m sequence to design a modiﬁed pCYC1m promoter
(pCYC1m(modiﬁed), Figure 6A). As shown in the left panel of
Figure 6B, the modiﬁed promoter did not respond to the wild-
type gRNAs (except for c4, which still perfectly matched target
sites within this modiﬁed promoter). However, this modiﬁed
promoter responded to a new set of gRNAs (cm1, cm2, and
cm5) that were designed to match the modiﬁed target sites.
The wild-type pCYC1m promoter did not respond to the new
set of gRNAs (cm1−cm6) (Figure 6B, left panel). These results
demonstrate that as little as a single base-pair mismatch is
suﬃcient to direct the crisprTF to one locus while preventing
activity at another locus.
To further demonstrate the potential of crisprTFs toward
constructing synthetic promoters and gRNAs that are
orthogonal with respect to each other, we tested three
randomly designed gRNAs (a1, a2 and a3 gRNAs) for their
ability to activate each other’s target sequences. As shown in
Figure 6C, each of the gRNAs exhibited high activity at their
cognate target sequences but low activity at noncognate
sequences. These results suggest that one can construct
synthetic promoters and gRNAs that are orthogonal with
respect to each other and to the host genome, especially within
eukaryotes with smaller genomes, such as yeasts.
During the course of the peer-review for this work, similar
systems for transcriptional control in eukaryotic cells were
described. Gilbert et al.59 demonstrated that CRISPR-mediated
gene repression and activation can be achieved in both yeast
and mammalian cells by using fusions of dCas9 with repressor
and activator domains respectively. Furthermore, Maeder et
al.60 and Perez-Pinera et al.61 showed synergistic CRISPR/Cas-
based gene activation in human cells with multiple gRNAs. In
this paper, we additionally show that both activation and
Figure 4. Synergistic and tunable activation of synthetic promoters
with arrayed operator sites upstream of pCYC1m in S. cerevisiae and
pMLPm in HEK293T cells using crisprTFs. (A) A schematic view of
the pCYC1m synthetic promoter with three a1_gRNA operator sites
(3× DNA sequences recognized by the a1_gRNA) arrayed upstream
of pCYC1m, thus named 3x(a1_op)_pCYC1m. (B) Increasing the
number of arrayed a1_gRNA operator sites upstream of pCYC1m
resulted in higher bfp expression in S. cerevisiae cells expressing the
a1_gRNA compared to the no gRNA controls. Error bars indicate the
standard error of the mean for three independent biological replicates.
(C) A schematic view of the pMLPm synthetic promoter with three
a1_gRNA operator sites arrayed upstream of pMLPm, thus named
3x(a1_op)_pMLPm. (D) Increasing the number of arrayed a1_gRNA
operator sites upstream of pMLPm resulted in higher yfp expression in
HEK293T cells when cotransfected with a1_gRNA and dCas9_VP64
versus when cotransfected with a1_gRNA and dCas9. Error bars
indicate the standard error of the mean for three independent
biological replicates.
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repression functions can be achieved with only one tran-
scription factor, by targeting dCas9_VP64 fusions to diﬀerent
regulatory sequences along a promoter. Our ﬁnding that one
can activate or repress the expression of a gene of interest by
directing a single protein to diﬀerent positions of a promoter is
advantageous for the eﬃcient design of synthetic transcriptional
networks or rewiring natural ones. This property obviates the
need for using separate orthogonal Cas9 protein fusions as
activators and repressors. Furthermore, we demonstrate that
more sophisticated regulatory motifs, such as small-molecule
responsive modules can be built for crisprTFs, thus enabling
external control of crisprTF-based transcriptional circuits. Such
synthetic modules can be interfaced with other regulatory
elements to achieve more complex regulation for synthetic
biology.
Our results show that dCas9 can be used as a customizable
RNA-guided DNA-binding platform for the regulation of gene
expression at natural and synthetic promoters in eukaryotic
cells. The ease of design and expression of customized gRNAs
in comparison to ZFs and TALEs make CRISPR-based
transcription factors appealing as synthetic TFs for modulating
endogenous gene expression as well as for synthetic biology.
The ability to customize the target site of dCas9 via the
expression of short gRNAs obviates the need to engineer
multiple orthogonal DBDs in order to construct complex
transcriptional circuits. This could potentially reduce the overall
metabolic burden on cells and enable the integration of more
complex synthetic computation and logic within living cells.62,63
More complex regulatory and logic circuits, such as cascades
and complex digital logics gates can be built by layering
crisprTFs. The possibility of integrating multiple inputs at a
single promoter expands the regulatory potential and provides
us with increased ﬂexibility that can be leveraged while
designing synthetic transcriptional networks or rewiring
endogenous pathways.
Furthermore, since both activation and repression functions
can be achieved with crisprTFs, the crisprTF platform may be
advantageous compared to noncoding RNA-based gene
regulatory platforms where only repression can be achieved.
In a way, crisprTFs combine the multiplexability of RNA-based
regulatory approaches with the ﬂexibility and rich functionality
repertoire of protein-based gene regulatory approaches: Cas9
can be functionalized with regulatory domains of interest (e.g.,
activation, repression, or epigenetic eﬀector) and then be
targeted to multiple loci using diﬀerent gRNAs.
Future work is needed to deﬁne the range of eﬀector
domains that can be used with dCas9 for a variety of regulatory
functions, including transcriptional regulation and epigenetic
modiﬁcations. In addition, the identiﬁcation, characterization,
and optimization of Cas9 homologues or evolved variants may
enable enhanced activity and speciﬁcity of this system.
Moreover, the ability to synthesize random libraries of
gRNAs opens the possibility for high-throughput perturbations
of transcriptional networks and screening for desirable
phenotypes. Ultimately, we envision that crisprTFs will enable
the regulation and perturbation of natural transcriptional
networks as well as the construction of complex synthetic
circuits at an unprecedented speed and scale.
■ METHODS
Strain and Plasmid Construction. Saccharomyces
cerevisiae. dCas9 (endonuclease-deﬁcient Cas9, with D10A
and H841A mutations relative to the wild-type sequence of S.
pyogenes Cas939) with an N-terminal SV40 nuclear localization
signal (NLS) was codon-optimized for expression in S. cerevisiae
and cloned into a pRS314 backbone under control of the
pTPGI promoter.23 The RNA-guided transcription factors
(crisprTFs) were built by fusing four repeats of the minimal
domain of the herpes simplex viral protein 16 (VP16) to the C-
terminus of dCas9 (dCas9_VP64). The crisprTF-expressing
plasmid was then integrated into the TRP1 locus of S. cerevisiae
W303.
The reporter plasmids were built by cloning yeast-enhanced
gfp under the control of the wild-type or modiﬁed pCYC1m
promoter into pRS406 using one-step Gibson assembly. The
reporters for the multiple-gRNA-binding-site experiment
(Figure 4A) were built by cloning the corresponding number
of binding sites upstream of the pCYC1m promoter driving
production of EBFP2. All reporters were integrated into the
bla1 locus of the integrated crisprTF plasmid.
To build gRNA-expressing plasmids, empty gRNA expressing
vectors were ﬁrst made by cloning the pRPR1 promoter (an
RNA-polymerase-III-dependent promoter44), the gRNA handle
(ﬂanked by HindIII and Xho1 sites), and the RPR terminator
Figure 5. Inducible crisprTF-guided activation of synthetic promoters. (A) Schematic of the aTc-inducible pRPR1_TetO promoter. Expression of
dCas9_VP64 is driven by the galactose-inducible pGAL1 promoter. A TetR operator site (1xTetO) was placed in the pRPR1 promoter to make an
aTc-responsive pRPR1_TetO promoter. Addition of aTc releases TetR-mediated repression on the pRPR1_TetO promoter and results in a1_gRNA
expression. (B) aTc-dependent bfp expression from a synthetic 6x(a1_op)_pCYC1m promoter. S. cerevisiae cells containing the circuit shown in (A)
were grown in galactose media with either 250 ng/mL aTc or no aTc. Error bars indicate the standard error of mean for three biological replicates.
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Figure 6. Constructing orthogonal crisprTF-responsive promoters. (A) A schematic view of gRNAs targeting the wild-type and modiﬁed pCYC1m
promoters in yeast. Only the c1-c8 gRNAs have perfect homology to the target sequences in pCYC1m. On the other hand, c1, c4, c5, and cm1-cm6
gRNAs have perfect homology to the sequences in the pCYC1m(modiﬁed) promoter. Mismatches between pCYC1m and pCYC1m(modiﬁed) are
marked by asterisks (*). (B) pCYC1m only responds to gRNAs that are perfectly matching gRNAs (c1-c8 gRNAs) and not to those that contain
mismatches (cm1−cm6 gRNAs). The pCYC1m(modiﬁed) promoter responds to the cm1−cm6 gRNAs. Those gRNAs that bind to the sequences
upstream of the TATA boxes activate gfp expression and those that target sequences downstream of the TATA boxes repress gfp expression. The c1
and c5 gRNAs have similarly neutral eﬀects on both the wild-type and modiﬁed promoters. Error bars indicate standard error of the mean for three
independent biological replicates. Asterisks (*) on each bar indicate statistically signiﬁcant activation or repression relative to no gRNA controls
(based on the two-sided Welch’s t test, p-value < 0.05). (C) Heat map illustrating the orthogonality of crisprTFs in human cells. Plasmids encoding
three orthogonal gRNAs (a1, a2, and a3 gRNAs) were cotransfected into HEK293T cells along with one of the three reporter plasmids (each
encoding 4× operator sites for a given gRNA) upstream of pMLPm promoter driving yfp expression. Only cognate interactions between gRNAs and
target binding sites resulted in signiﬁcant activation. The standard error of the mean of YFP ﬂuorescence for three independent biological replicates
is indicated in each cell of the heat-map plot.
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into the SacI and KpnI sites of either the pRS423 or pRS425
plasmid using one-step Gibson assembly. The speciﬁcity
determinant sequence (SDS) for each gRNA was then cloned
into the HindIII site of these vectors by one-step Gibson
assembly. Sequences of the constructs used in this study are
listed in Table S1, Supporting Information.
HEK293T Cells. To construct the mammalian dCas9_VP64
expressing plasmid, we ﬁrst introduced D10A and H841A
mutations into hCas937 (Addgene, Plasmid #41815). Then,
three repeats of SV40 NLS (3xNLS) were fused to the C-
terminus of the mutated hCas9 using a PCR-based assembly
protocol. Using a multipart Gibson assembly protocol, the
immediate-early promoter of cytomegalovirus (pCMV),
dCas9_3xNLS, VP64, and SV40 polyA terminator were cloned
into the NotI site of the pG5-Luc plasmid (Promega). To
monitor successfully transfected cells by ﬂow cytometry, we
replaced the original luciferase gene in pG5-Luc with mKATE
(Evrogen). The resulting pPGK1_mKATE cassette served as a
constitutive ﬂuorescent protein control that was used to gate
for the presence of the crisprTF-expressing plasmid with ﬂow
cytometry.
The gRNA expression plasmids were constructed by cloning
the 138 bp human U6 promoter (an RNA-polymerase-III-
dependent promoter48), along with the gRNA handle and
terminator into a plasmid containing pPGK1-eBFP2 ﬂanked by
the SV40 polyA terminator (a gift from Lior Nissim). A SacI
site was placed at the 3′-end of the U6 promoter to enable the
cloning of diﬀerent speciﬁcity determining sequences for each
gRNA. The reporters were assembled into the gRNA-
expressing plasmid through a one-step Gibson assembly
reaction, where the upstream polyadenylation signal and
transcriptional pause site from pG5-Luc, along with a 41 bp,
minimal adenovirus type 2 major late promoter (pMLPm),
mYFP, and HSV polyA signal were cloned into the AatII site of
the gRNA-expressing plasmids.
For the synthetic promoter experiments, additional gRNA
operator sites were cloned in the NheI site upstream of the
pMLPm promoter (see Supporting Information). For the
repression experiments, dCas9_KRAB was constructed by
cloning a 366 bp KRAB domain to the C-terminus of dCas9.
GCCACC was used as the Kozak sequence for the expression
of dCas9_VP64, mYFP, eBFP2, and mKATE.
Unless directly targeted by gRNAs for repression assays, the
mKATE ﬂuorescent protein on the crisprTF-expression
plasmid and the eBFP2 ﬂuorescent protein on the reporter/
gRNA plasmid served as our gating controls for ﬂow cytometry
analysis.
Fluorescence Assays. To assess expression of the reporter
constructs, yeast cells expressing diﬀerent gRNAs (or no gRNA
as control) were grown overnight (900 rpm, 30C) in 96-deep-
well plates in yeast minimal media supplemented with glucose
with appropriate selection (three independent cultures for each
sample). Ten microliters of these cultures were then transferred
into fresh media supplemented with galactose +250 ng/mL
anhydrotetracycline (aTc) and grown for 20 h (900 rpm, 30C)
before analysis by ﬂow cytometry.
For the human cell culture experiments, HEK293T kidney
epithelial cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% (v/v) fetal bovine
serum (FBS), 1% glutamine, and 1% penicillin/streptomycin.
Cells were grown under 5% CO2 at 37 °C. HEK293T cells were
transfected with Fugene-HD transfection reagent (Promega)
and assayed for gene expression with ﬂow cytometry at 48 h
post transfection.
An LSR Fortessa II ﬂow cytometer equipped with 405 nm,
488 nm, and 561 nm lasers was used for all the experiments.
GFP/YFP, BFP, and mKATE levels were detected using 488/
FITC, 405/Paciﬁc-Blue, and 561/TX-red laser/ﬁlter sets,
respectively. All samples were uniformly gated by forward
and side scatter. Additional gating for the presence of red and
blue ﬂuorophores was applied to the HEK293T samples to
ensure only cells successfully transfected with both the crisprTF
and the reporter/gRNA plasmids are analyzed. For each gated
sample, the mean ﬂuorescence per cell was calculated. Three
independent biological samples were used to calculate the mean
and standard error of the mean for each data point.
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